• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A simultaneous oral and intramuscular prime/sublingual boost with a DNA/Modified Vaccinia Ankara viral vector-based vaccine induces simian immunodeficiency virus-specific systemic and mucosal immune responses in juvenile rhesus macaques.使用基于DNA/改良痘苗病毒安卡拉病毒载体的疫苗进行口服和肌肉注射同时初免/舌下加强免疫,可在幼年恒河猴中诱导猿猴免疫缺陷病毒特异性的全身和黏膜免疫反应。
J Med Primatol. 2018 Oct;47(5):288-297. doi: 10.1111/jmp.12372. Epub 2018 Sep 11.
2
Oral Coadministration of an Intramuscular DNA/Modified Vaccinia Ankara Vaccine for Simian Immunodeficiency Virus Is Associated with Better Control of Infection in Orally Exposed Infant Macaques.口服肌肉注射型DNA/改良安卡拉痘苗病毒疫苗用于猿猴免疫缺陷病毒,与口服暴露的幼猴感染得到更好控制相关。
AIDS Res Hum Retroviruses. 2019 Mar;35(3):310-325. doi: 10.1089/AID.2018.0180. Epub 2018 Nov 27.
3
CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.CD40L佐剂化DNA/改良安卡拉痘苗病毒猿猴免疫缺陷病毒SIV239疫苗可增强SIV特异性体液免疫和细胞免疫,并提高对异源SIVE660黏膜攻击的保护作用。
J Virol. 2014 Sep 1;88(17):9579-89. doi: 10.1128/JVI.00975-14. Epub 2014 Jun 11.
4
Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.展示三聚体猴免疫缺陷病毒(SIV)包膜糖蛋白160的病毒样颗粒增强了恒河猴中DNA/改良痘苗病毒安卡拉SIV疫苗诱导的抗体反应的广度。
J Virol. 2016 Sep 12;90(19):8842-54. doi: 10.1128/JVI.01163-16. Print 2016 Oct 1.
5
Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes.四种不同黏膜途径给予雌性恒河猴的猴免疫缺陷病毒 DNA、rMVA 和病毒颗粒疫苗方案的免疫原性。
J Virol. 2013 Apr;87(8):4738-50. doi: 10.1128/JVI.03531-12. Epub 2013 Feb 13.
6
Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.用减毒活疫苗NYVAC/猴免疫缺陷病毒SIV(gpe)重组疫苗进行黏膜免疫和全身免疫,均可在猕猴的黏膜组织中引发针对gag的CD8(+) T细胞应答。
J Virol. 2002 Nov;76(22):11659-76. doi: 10.1128/jvi.76.22.11659-11676.2002.
7
Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.预先存在的牛痘病毒免疫会降低 SIV 特异性细胞免疫,但不会降低体液免疫和 DNA/MVA 疫苗的功效。
J Immunol. 2010 Dec 15;185(12):7262-73. doi: 10.4049/jimmunol.1000751. Epub 2010 Nov 12.
8
Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.针对婴儿恒河猴口服 SIV 挑战的 VSV-SIV/MVA-SIV 疫苗方案的部分疗效。
Vaccine. 2011 Apr 12;29(17):3124-37. doi: 10.1016/j.vaccine.2011.02.051. Epub 2011 Mar 4.
9
Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.病毒载体、初免-加强 SIV 疫苗方案在婴儿恒河猴中的免疫原性:减毒水疱性口炎病毒(VSV)和改良安卡拉痘苗病毒(MVA)重组 SIV 疫苗与活减毒 SIV 相比。
Vaccine. 2010 Feb 10;28(6):1481-92. doi: 10.1016/j.vaccine.2009.11.061. Epub 2009 Dec 6.
10
A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques.一种 Prime/Boost 疫苗方案改变了直肠微生物组,并影响了感染猴免疫缺陷病毒后的雄性和雌性恒河猴的免疫反应和病毒血症控制。
J Virol. 2020 Nov 23;94(24). doi: 10.1128/JVI.01225-20.

引用本文的文献

1
SARS-CoV-2 sublingual vaccine with RBD antigen and poly(I:C) adjuvant: Preclinical study in cynomolgus macaques.含RBD抗原和聚肌胞苷酸佐剂的新型冠状病毒2型舌下疫苗:食蟹猴的临床前研究
Biol Methods Protoc. 2023 Sep 13;8(1):bpad017. doi: 10.1093/biomethods/bpad017. eCollection 2023.
2
Advances in the polymeric delivery of nucleic acid vaccines.核酸疫苗的聚合物传递进展。
Theranostics. 2022 May 13;12(9):4081-4109. doi: 10.7150/thno.70853. eCollection 2022.
3
Sublingual Boosting with a Novel Mucoadhesive Thermogelling Hydrogel Following Parenteral CAF01 Priming as a Strategy Against Chlamydia trachomatis.在采用肠胃外CAF01启动后,使用新型粘膜粘附热凝胶水凝胶进行舌下给药增强免疫,作为一种抗沙眼衣原体的策略。
Adv Healthc Mater. 2022 Jun;11(11):e2102508. doi: 10.1002/adhm.202102508. Epub 2022 Mar 13.
4
SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques.SARS-CoV-2 疫苗可在幼年恒河猴中引发持久的免疫应答。
Sci Immunol. 2021 Jun 15;6(60). doi: 10.1126/sciimmunol.abj3684.
5
T Cells Induced by Vaccination and Following SIV Challenge Support Env-Specific Humoral Immunity in the Rectal-Genital Tract and Circulation of Female Rhesus Macaques.接种疫苗及感染猴免疫缺陷病毒(SIV)后诱导产生的T细胞可支持恒河猴雌性直肠生殖道及循环系统中针对Env的体液免疫。
Front Immunol. 2021 Jan 28;11:608003. doi: 10.3389/fimmu.2020.608003. eCollection 2020.
6
MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease.MVA载体疫苗可抑制转基因小鼠上、下呼吸道中的SARS-CoV-2复制并预防致死性疾病。
bioRxiv. 2021 Jan 1:2020.12.30.424878. doi: 10.1101/2020.12.30.424878.
7
Comparative Evaluation of Prophylactic SIV Vaccination Modalities Administered to the Oral Cavity.口腔途径预防性 SIV 疫苗接种方式的比较评估。
AIDS Res Hum Retroviruses. 2020 Dec;36(12):984-997. doi: 10.1089/AID.2020.0157. Epub 2020 Oct 27.
8
HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge.经无针口腔注射的 HIV-1 疫苗接种可诱导强烈的黏膜免疫,并可预防 SHIV 攻击。
Nat Commun. 2019 Feb 18;10(1):798. doi: 10.1038/s41467-019-08739-4.
9
Oral Coadministration of an Intramuscular DNA/Modified Vaccinia Ankara Vaccine for Simian Immunodeficiency Virus Is Associated with Better Control of Infection in Orally Exposed Infant Macaques.口服肌肉注射型DNA/改良安卡拉痘苗病毒疫苗用于猿猴免疫缺陷病毒,与口服暴露的幼猴感染得到更好控制相关。
AIDS Res Hum Retroviruses. 2019 Mar;35(3):310-325. doi: 10.1089/AID.2018.0180. Epub 2018 Nov 27.

本文引用的文献

1
HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy.在抗逆转录病毒治疗期间,HIV持续存在于来自结肠和血液的CCR6+CD4+ T细胞中。
AIDS. 2017 Jan 2;31(1):35-48. doi: 10.1097/QAD.0000000000001309.
2
Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.在接种减毒结核分枝杆菌或牛分枝杆菌卡介苗的幼年猕猴中,平衡训练有素的免疫与持续免疫激活以及感染猴免疫缺陷病毒的风险。
Clin Vaccine Immunol. 2017 Jan 5;24(1). doi: 10.1128/CVI.00360-16. Print 2017 Jan.
3
Dances with cytokines, featuring TFH cells, IL-21, IL-4 and B cells.与细胞因子共舞,主角是滤泡辅助性T细胞、白细胞介素-21、白细胞介素-4和B细胞。
Nat Immunol. 2016 Sep 20;17(10):1135-6. doi: 10.1038/ni.3561.
4
Induction of Th1-Biased T Follicular Helper (Tfh) Cells in Lymphoid Tissues during Chronic Simian Immunodeficiency Virus Infection Defines Functionally Distinct Germinal Center Tfh Cells.慢性猴免疫缺陷病毒感染期间淋巴组织中Th1偏向性滤泡辅助性T细胞(Tfh)的诱导定义了功能不同的生发中心Tfh细胞。
J Immunol. 2016 Sep 1;197(5):1832-42. doi: 10.4049/jimmunol.1600143. Epub 2016 Aug 1.
5
HIV-specific Th2 and Th17 responses predict HIV vaccine protection efficacy.HIV特异性Th2和Th17反应可预测HIV疫苗的保护效果。
Sci Rep. 2016 Jun 21;6:28129. doi: 10.1038/srep28129.
6
Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques.疫苗引发的黏膜和全身抗体反应与恒河猴幼猴体内猿猴免疫缺陷病毒血症的降低有关。
J Virol. 2016 Jul 27;90(16):7285-7302. doi: 10.1128/JVI.00481-16. Print 2016 Aug 15.
7
Time to prioritise the UNAIDS 90-90-90 targets for infants.是时候优先考虑联合国艾滋病规划署针对婴儿的90-90-90目标了。
Lancet HIV. 2016 Jun;3(6):e241-3. doi: 10.1016/S2352-3018(16)30013-3. Epub 2016 May 3.
8
Challenges in the Elimination of Pediatric HIV-1 Infection.消除儿童HIV-1感染面临的挑战。
N Engl J Med. 2016 Feb 25;374(8):761-70. doi: 10.1056/NEJMra1505256.
9
Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.用重组痘苗病毒初免和肌肉注射蛋白加强进行口服免疫可保护猕猴免受直肠内猿猴-人类免疫缺陷病毒攻击。
Clin Vaccine Immunol. 2015 Dec 30;23(3):204-12. doi: 10.1128/CVI.00597-15.
10
Preparation of Cell Cultures and Vaccinia Virus Stocks.细胞培养物和痘苗病毒储备液的制备。
Curr Protoc Microbiol. 2015 Nov 3;39:14A.3.1-14A.3.18. doi: 10.1002/9780471729259.mc14a03s39.

使用基于DNA/改良痘苗病毒安卡拉病毒载体的疫苗进行口服和肌肉注射同时初免/舌下加强免疫,可在幼年恒河猴中诱导猿猴免疫缺陷病毒特异性的全身和黏膜免疫反应。

A simultaneous oral and intramuscular prime/sublingual boost with a DNA/Modified Vaccinia Ankara viral vector-based vaccine induces simian immunodeficiency virus-specific systemic and mucosal immune responses in juvenile rhesus macaques.

作者信息

Curtis Alan D, Jensen Kara, Van Rompay Koen K A, Amara Rama R, Kozlowski Pamela A, De Paris Kristina

机构信息

Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

California National Primate Research Center, University of California, Davis, California.

出版信息

J Med Primatol. 2018 Oct;47(5):288-297. doi: 10.1111/jmp.12372. Epub 2018 Sep 11.

DOI:10.1111/jmp.12372
PMID:30204253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6158111/
Abstract

BACKGROUND

A pediatric vaccine to prevent breast milk transmission of human immunodeficiency virus (HIV) may generate greater immune responses at viral entry sites if given by an oral route.

METHODS

We compared immune responses induced in juvenile macaques by prime/boosting with simian immunodeficiency virus (SIV)-expressing DNA/modified vaccinia Ankara virus (MVA) by the intramuscular route (IM), the oral (O)/tonsillar routes (T), the O/sublingual (SL) routes, and O+IM/SL routes.

RESULTS

O/T or O/SL immunization generated SIV-specific T cells in mucosal tissues but failed to induce SIV-specific IgA in saliva or stool or IgG in plasma. IM/IM or O+IM/SL generated humoral and cellular responses to SIV. IM/IM generated greater frequencies of T in spleen, but O+IM/SL animals had higher avidity plasma IgG and more often demonstrated mucosal IgA responses.

CONCLUSION

These results suggest that codelivery of HIV DNA/MVA vaccines by the oral and IM routes might be optimal for generating both systemic and mucosal antibodies.

摘要

背景

一种预防人类免疫缺陷病毒(HIV)通过母乳传播的儿科疫苗,如果通过口服途径给药,可能会在病毒进入部位产生更强的免疫反应。

方法

我们比较了通过肌肉注射(IM)、口服(O)/扁桃体途径(T)、口服/舌下(SL)途径以及口服+肌肉注射/舌下途径,用表达猿猴免疫缺陷病毒(SIV)的DNA/改良痘苗病毒安卡拉(MVA)进行初免/加强免疫后,幼年猕猴体内诱导产生的免疫反应。

结果

口服/扁桃体或口服/舌下免疫在黏膜组织中产生了SIV特异性T细胞,但未能在唾液或粪便中诱导产生SIV特异性IgA,也未能在血浆中诱导产生IgG。肌肉注射/肌肉注射或口服+肌肉注射/舌下免疫产生了针对SIV的体液和细胞免疫反应。肌肉注射/肌肉注射在脾脏中产生的T细胞频率更高,但口服+肌肉注射/舌下免疫的动物血浆IgG亲和力更高,并且更常表现出黏膜IgA反应。

结论

这些结果表明,通过口服和肌肉注射途径联合递送HIV DNA/MVA疫苗可能是产生全身和黏膜抗体的最佳方式。